Department of Endocrine and Breast Surgery;
The First Affiliated Hospital of Chongqing Medical University;
Chongqing 400016;
China;
Department of Physics;
Applied Optics Beijing Area Major Laboratory;
Beijing Normal University;
Beijing 100875;
China;
Additional chemotherapy; HER2-overexpressing breast cancer; residual disease; T-DM1;